There is a real need for new treatment options for the complications of #Crohns disease. TiGenix is committed to working to bring innovative new medicines to patients #WorldIBDDay
Maria Pascual, VP Regulatory Affairs and Corporate Quality at TiGenix: “Today’s approval reflects our deep understanding and recognized leadership in the development of allogeneic stem cells and our firm commitment to developing innovative therapies for medical needs.” #crohns
TiGenix and @TakedaPharma receive European approval for an allogeneic stem cell therapy to treat a complication of Crohn’s disease #crohns#IBD https://t.co/2cMTF3P97n
[VIDEO] TiGenix focuses on the anti-inflammatory properties of adipose-derived stem cells to make new therapies. Discover how it works
https://t.co/VZqkYNyzg8 via @YouTube
-There is a real need for new treatment options for the complications of #Crohns disease. TiGenix is committed to working to bring innovative new medicines to patients #CCAwarenessWeek#IBD@CrohnsColitisFn